Anti-EGFR therapy: strategies in head and neck squamous cell carcinoma.
Autor(a) principal: | |
---|---|
Data de Publicação: | 2016 |
Outros Autores: | , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/1822/46231 |
Resumo: | Epidermal growth factor receptor (EGFR) is a tyrosine kinase receptor that activates downstream signaling pathways, including the Ras-MEK-Erk and PI3K-AKT pathways, leading to cell proliferation, resistance to apoptosis, angiogenesis and the ability to metastasize. EGFR overexpression is a significant finding in cancer, particularly in head and neck cancer, where it is also associated with a poor prognosis. In recent years, several molecules have been designed to inhibit EGFR activation. Among the many available anti-EGFR drugs, only cetuximab was approved for the treatment of head and neck cancers. However, no predictive biomarkers of cetuximab response are currently known. In the present review, we provide an updated assessment of EGFR biology and its clinical impact in head and neck cancers. A special emphasis is placed on novel patents of EGFR-inhibitors that are anticipated to diversify the anti-EGFR therapies available to treat head and neck cancers. In particular, we outline a new class of irreversible multi-target inhibitors (e.g. afatinib, icotinib, CUDC-101), which may significantly contribute to new head and neck cancer therapies. |
id |
RCAP_d495bab9b976b1b01ecf1467127bde84 |
---|---|
oai_identifier_str |
oai:repositorium.sdum.uminho.pt:1822/46231 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Anti-EGFR therapy: strategies in head and neck squamous cell carcinoma.Anti-EGFR patentsEGFREGFR overexpressionHead and neck squamous cell carcinomaTyrosine kinase inhibtorTargeted therapiestyrosine kinase inhibtorsScience & TechnologyEpidermal growth factor receptor (EGFR) is a tyrosine kinase receptor that activates downstream signaling pathways, including the Ras-MEK-Erk and PI3K-AKT pathways, leading to cell proliferation, resistance to apoptosis, angiogenesis and the ability to metastasize. EGFR overexpression is a significant finding in cancer, particularly in head and neck cancer, where it is also associated with a poor prognosis. In recent years, several molecules have been designed to inhibit EGFR activation. Among the many available anti-EGFR drugs, only cetuximab was approved for the treatment of head and neck cancers. However, no predictive biomarkers of cetuximab response are currently known. In the present review, we provide an updated assessment of EGFR biology and its clinical impact in head and neck cancers. A special emphasis is placed on novel patents of EGFR-inhibitors that are anticipated to diversify the anti-EGFR therapies available to treat head and neck cancers. In particular, we outline a new class of irreversible multi-target inhibitors (e.g. afatinib, icotinib, CUDC-101), which may significantly contribute to new head and neck cancer therapies.The authors would like to acknowledge Dr. Laura Mussel white for critical revision of the manuscript. André L. Carvalho and Rui M. Reis have a National Counsel of Technological and Scientific Development (CNPq) scholarship. A.C.C, has a FAPESP (2013/13834-7) scholarship.info:eu-repo/semantics/publishedVersionBentham Science PublishersUniversidade do MinhoOliveira-Silva, Renato J.Carvalho, Ana-Carolina deViana, Luciano de SouzaReis, R. M.20162016-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/1822/46231eng1574-892810.2174/157489281166616030912123826955963http://www.eurekaselect.com/140320/articleinfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-07-21T12:22:49Zoai:repositorium.sdum.uminho.pt:1822/46231Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T19:16:22.650422Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Anti-EGFR therapy: strategies in head and neck squamous cell carcinoma. |
title |
Anti-EGFR therapy: strategies in head and neck squamous cell carcinoma. |
spellingShingle |
Anti-EGFR therapy: strategies in head and neck squamous cell carcinoma. Oliveira-Silva, Renato J. Anti-EGFR patents EGFR EGFR overexpression Head and neck squamous cell carcinoma Tyrosine kinase inhibtor Targeted therapies tyrosine kinase inhibtors Science & Technology |
title_short |
Anti-EGFR therapy: strategies in head and neck squamous cell carcinoma. |
title_full |
Anti-EGFR therapy: strategies in head and neck squamous cell carcinoma. |
title_fullStr |
Anti-EGFR therapy: strategies in head and neck squamous cell carcinoma. |
title_full_unstemmed |
Anti-EGFR therapy: strategies in head and neck squamous cell carcinoma. |
title_sort |
Anti-EGFR therapy: strategies in head and neck squamous cell carcinoma. |
author |
Oliveira-Silva, Renato J. |
author_facet |
Oliveira-Silva, Renato J. Carvalho, Ana-Carolina de Viana, Luciano de Souza Reis, R. M. |
author_role |
author |
author2 |
Carvalho, Ana-Carolina de Viana, Luciano de Souza Reis, R. M. |
author2_role |
author author author |
dc.contributor.none.fl_str_mv |
Universidade do Minho |
dc.contributor.author.fl_str_mv |
Oliveira-Silva, Renato J. Carvalho, Ana-Carolina de Viana, Luciano de Souza Reis, R. M. |
dc.subject.por.fl_str_mv |
Anti-EGFR patents EGFR EGFR overexpression Head and neck squamous cell carcinoma Tyrosine kinase inhibtor Targeted therapies tyrosine kinase inhibtors Science & Technology |
topic |
Anti-EGFR patents EGFR EGFR overexpression Head and neck squamous cell carcinoma Tyrosine kinase inhibtor Targeted therapies tyrosine kinase inhibtors Science & Technology |
description |
Epidermal growth factor receptor (EGFR) is a tyrosine kinase receptor that activates downstream signaling pathways, including the Ras-MEK-Erk and PI3K-AKT pathways, leading to cell proliferation, resistance to apoptosis, angiogenesis and the ability to metastasize. EGFR overexpression is a significant finding in cancer, particularly in head and neck cancer, where it is also associated with a poor prognosis. In recent years, several molecules have been designed to inhibit EGFR activation. Among the many available anti-EGFR drugs, only cetuximab was approved for the treatment of head and neck cancers. However, no predictive biomarkers of cetuximab response are currently known. In the present review, we provide an updated assessment of EGFR biology and its clinical impact in head and neck cancers. A special emphasis is placed on novel patents of EGFR-inhibitors that are anticipated to diversify the anti-EGFR therapies available to treat head and neck cancers. In particular, we outline a new class of irreversible multi-target inhibitors (e.g. afatinib, icotinib, CUDC-101), which may significantly contribute to new head and neck cancer therapies. |
publishDate |
2016 |
dc.date.none.fl_str_mv |
2016 2016-01-01T00:00:00Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/1822/46231 |
url |
http://hdl.handle.net/1822/46231 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
1574-8928 10.2174/1574892811666160309121238 26955963 http://www.eurekaselect.com/140320/article |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Bentham Science Publishers |
publisher.none.fl_str_mv |
Bentham Science Publishers |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799132612207312896 |